Press Releases

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

Press Releases

News Releases

Date Title and Summary
Toggle Summary KemPharm Announces FDA Approval of AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules, for oral use, CII), A New Once-Daily Treatment for ADHD
Conference Call and Live Audio Webcast Scheduled for Tomorrow, Wednesday, March 3 , at 8:30 a.m. ET CELEBRATION, Fla. , March 02, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today
Toggle Summary KemPharm Receives FDA Clearance to Initiate KP879 Clinical Program for the Treatment of Stimulant Use Disorder
Financial Restructuring and Nasdaq Re-Listing Process Completed CELEBRATION, Fla. , Jan. 27, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that the U.S.
Toggle Summary KemPharm’s KP415 and Serdexmethylphenidate (SDX) Prodrug to be Featured in Multiple Sessions at the 2021 APSARD Virtual Conference
Combination of Oral and Poster Presentations Scheduled for January 15, 2021 CELEBRATION, Fla. , Jan. 14, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that research
Toggle Summary KemPharm Participating in BIO @ JPM and Fierce JPM Week 2021 Virtual Events During “J.P. Morgan Week 2021”
CELEBRATION, Fla. , Jan. 13, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the company is participating in BIO @ JPM and Fierce JPM Week 2021.  Both events are being
Toggle Summary KemPharm Announces Pricing of $50 Million Public Offering of Common Stock and Warrants and Uplisting to The Nasdaq Capital Market
Common stock will begin trading on The Nasdaq Capital Market under the ticker symbol “KMPH” today, January 8, 2021 CELEBRATION, Fla. , Jan. 08, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary
Toggle Summary KemPharm Announces 1-for-16 Reverse Stock Split
CELEBRATION, Fla. , Dec. 23, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Company's Board of Directors has approved a 1-for-16 reverse stock split of its shares of
Toggle Summary KemPharm Files IND for KP879 for the Treatment of Stimulant Use Disorder
CELEBRATION, Fla. , Dec. 22, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced it has filed an Investigational New Drug (IND) application with the U.S.
Toggle Summary KemPharm Participates in KP415 Late-Cycle Communication Meeting with FDA
CELEBRATION, Fla. , Dec. 02, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Company participated in a late-cycle communication meeting on December 1, 2020 , with the
Toggle Summary REMINDER: KemPharm and Corium to Co-Host “KP415 Market Opportunity and Commercialization Strategy” Investor Event
Online Event Scheduled for Wednesday, December 2, 2020 at 10:00 a.m., ET CELEBRATION, Fla. , Nov. 30, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, will co-host an online investor event
Toggle Summary KemPharm Provides Update on Development Pipeline
IND for KP879 Expected to be Filed Before Year-End 2020; New Prodrug Candidate   Added to Pipeline ,   Targeting Rare CNS Disease , Idiopathic Hypersomnia (IH) CELEBRATION, Fla. , Nov. 23, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company focused on the